Durvalumab (anti-PD-L1) PD-1/PD-L1 inhibitor | Read Reviews & Product Use Citations

Durvalumab (anti-PD-L1) is a selective, high affinity human IgG1 mAb that blocks programmed cell death ligand-1 (PD-L1) binding to PD-1 (IC50=0.1 nM) and CD80 (IC50=0.04 nM). MW=146.3 kDa.

Click to purchase the isotype control of Durvalumab (anti-PD-L1)

19 Citations

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: Purity: 99.68% Protein concentration: 5 mg/ml Endotoxin Level: <1 EU/mg

99.68

Specificity

Name	Citation	PD-1/PD-L1 interaction	PD-1	PD-L1	PD-1/PD-L1	Others
GS-4224	0	++++			++++
INCB086550	1	++			++
BMS-1001	0	+			+
BMS-1166	8	+++
PD-1/PD-L1 Inhibitor 3	13	+++
BMS-1	13	++
BMS202	26	+
CA-170 (AUPM-170)	0			✔
SR 0987	1		✔			IL17,RORγt
Spartalizumab (anti-PD-1)	3		✔
Camrelizumab (anti-PD-1)	2		✔
AUNP-12	3			✔

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description	Durvalumab (anti-PD-L1) is a selective, high affinity human IgG1 mAb that blocks programmed cell death ligand-1 (PD-L1) binding to PD-1 (IC50=0.1 nM) and CD80 (IC50=0.04 nM). MW=146.3 kDa.
Features	Human IgG1
Targets/IC₅₀/Ki	PD-L1/CD80 (HTRF assay) 0.04 nM PD-1/PD-L1 interaction (HTRF assay) 0.1 nM
In vitro	The labeled radioligand shows good affinity to high PD-L1 expression cells and could be blocked with excess unlabeled intact durvalumab.
Cell Research	The A549 and H460 cells were cultured in six-well plates (~106 cells/well) and divided into two groups. All of the wells were incubated with 5% BSA for blocking nonspecific binding. Group A was presaturated with 100-fold excess of unlabeled durvalumab to block the binding of ¹²⁴I-Durva-F(ab′)₂, and group B had only the medium added. After 30 min, 2 nM of ¹²⁴I-Durva-F(ab′)₂ was added to each group and incubated for 1 h at 37 °C in a cell incubator. After supernatant collection, the cells were lysed using 2 M of NaOH.
In vivo	The peak tumor uptake of ¹²⁴I-Durva-F(ab’)₂ was close to ¹²⁴I-Durva, but much earlier (5.29±0.42% ID/g for 124I-Durva-F(ab’)₂ at 12 h vs 5.18±0.73% ID/g for ¹²⁴I-Durva at 48 h). Compared with ¹²⁴I-Durva, an accelerated blood clearance was observed for ¹²⁴I-Durva-F(ab’)₂, allowing for a higher tumor-to-background ratio.
Animal Research	Animal Models: H460 and A549 tumor-bearing mice Dosages: 20 μCi Administration: i.v.
References	[1] https://pubmed.ncbi.nlm.nih.gov/35244407/

Product Details

CAS No.	1428935-60-7
Isotype	Human IgG1
Source	CHO cells
Sterility	0.2 μM filtered
Formulation	100 mM Pro-Ac, 20 mM Arg, pH 5.0
Storage (From the date of receipt)	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to store the antibody?

Answer:
Store the undiluted solution at 4 °C in the dark. Freezing antibodies can result in a loss of activity caused by the freezing/thawing process. Diluting antibodies to working concentrations and storing at 4°C for more than a day should be avoided. Additionally, make sure to keep the antibody sterile. Under these storage conditions, your antibodies should remain active for up to one year and oftentimes longer.